Differences in lung bioavailability between different propellants for fluticasone propionate

Andrew M. Wilson; Erika J. Sims; Linda C. Orr; Brian J. Lipworth

doi:10.1016/S0140-6736(99)03581-3

Differences in lung bioavailability between different propellants for fluticasone propionate

Andrew M. Wilson, Erika J. Sims, Linda C. Orr, Brian J. Lipworth

Research output: Contribution to journal › Letter › peer-review

20 Citations (Scopus)

Abstract

The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

Original language	English
Pages (from-to)	1357-8
Number of pages	2
Journal	Lancet
Volume	354
Issue number	9187
DOIs	https://doi.org/10.1016/S0140-6736(99)03581-3
Publication status	Published - 16 Oct 1999

Access to Document

10.1016/S0140-6736(99)03581-3

Cite this

@article{b7e934537a814be28c69fc5071c00f13,

title = "Differences in lung bioavailability between different propellants for fluticasone propionate",

abstract = "The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.",

author = "Wilson, {Andrew M.} and Sims, {Erika J.} and Orr, {Linda C.} and Lipworth, {Brian J.}",

year = "1999",

month = oct,

day = "16",

doi = "10.1016/S0140-6736(99)03581-3",

language = "English",

volume = "354",

pages = "1357--8",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9187",

}

TY - JOUR

T1 - Differences in lung bioavailability between different propellants for fluticasone propionate

AU - Wilson, Andrew M.

AU - Sims, Erika J.

AU - Orr, Linda C.

AU - Lipworth, Brian J.

PY - 1999/10/16

Y1 - 1999/10/16

N2 - The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

AB - The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

U2 - 10.1016/S0140-6736(99)03581-3

DO - 10.1016/S0140-6736(99)03581-3

M3 - Letter

C2 - 10533870

SN - 0140-6736

VL - 354

SP - 1357

EP - 1358

JO - Lancet

JF - Lancet

IS - 9187

ER -

Differences in lung bioavailability between different propellants for fluticasone propionate

Abstract

Access to Document

Fingerprint

Cite this